Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113251 · ClinicalTrials.gov registry record · Phase 3
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
A Phase 3 study of Breast Cancer and Breast Neoplasms, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 927
- Enrollment target
- 20
- Study locations
NCT05113251 is a Phase 3 study of Breast Cancer and Breast Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 927 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05113251, a Phase 3 study of Breast Cancer and Breast Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 927 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Trastuzumab Deruxtecan
- DRUG Pertuzumab
Study Locations (20)
California
- Research Site - Beverly Hills
- Research Site - Glendale
- Research Site - Los Alamitos
- Research Site - Orange
Kentucky
- Research Site - Lexington
- Research Site - Louisville
New Jersey
- Research Site - East Brunswick
- Research Site - Summit
Tennessee
- Research Site - Germantown
- Research Site - Nashville
Arkansas
- Research Site - Springdale
Connecticut
- Research Site - New Haven
Indiana
- Research Site - Fort Wayne
Louisiana
- Research Site - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05113251
The ClinicalTrials.gov registry entry for NCT05113251 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 927 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT05113251 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Kentucky, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05113251 about?
NCT05113251 is a clinical study titled "Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer". This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
What is the current status of trial NCT05113251?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 927 participants. The study started on 2021-10-25. Estimated completion is 2027-04-30.
What conditions does trial NCT05113251 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms, HER2-positive Early Breast Cancer.
What interventions are being tested in trial NCT05113251?
The interventions under investigation include: Trastuzumab (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Trastuzumab Deruxtecan (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT05113251?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05113251 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.